June 4, 2019

Posts published in June 4, 2019

Comprehensive PIK3CA Mutation Analysis

PIK3CA Comprehensive Testing & Breast Cancer Profiling, PIK3CA

  When you order GTC Breast Cancer Profile   The FDA has approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after […]

Read More